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• Pre-eclampsia is a condition               
in pregnant women marked by an 
increase in blood pressure and 
protein in urine after 20 weeks 
gestation.
• Providing high quality antenatal 
care improves the prevention and 
early detection of pre-eclampsia 
and can prevent its progression to 
eclampsia.
• Eclampsia is a life-threatening 
condition characterized by 
convulsions in women with  
pre-eclampsia.
• Women in developing countries 
are 300 times more likely to die 
from eclampsia than women in 
developed countries.
• Prescribing low-dose aspirin and 
calcium to at-risk women can 
lower their risk of developing  
pre-eclampsia and eclampsia.
• Severe pre-eclampsia can be 
managed by administering 
anti-hypertensive drugs and 
magnesium sulphate (MgSO4).
• MgSO4 is the safest and most 
effective treatment for severe 
PE/E. 
• Pre-eclampsia and other 
hypertensive disorders in 
pregnancy increase the risk of pre-
term births, which can lead to low 
birth weight, anemia, and stunting.
• Improved prevention, increased 
detection, and effective treatment 
of PE/E can prevent unnecessary 
maternal and newborn deaths.
PE/E in Brief
THE PROBLEM
Each day around the world, 830 women die from pregnancy- and childbirth-
related causes. In sub-Saharan Africa, 200,000 women die annually, and 
in Southern Asia 66,000 die each year. The second most common cause 
(after postpartum hemorrhage) is pre-eclampsia and eclampsia (PE/E)—life-
threatening, high blood pressure and excess protein in the urine after 20 
weeks gestation. These deaths are preventable, yet essential medicines and 
tools to treat this disorder are often unavailable in low-resource settings.
PE/E most often occurs during the second half of pregnancy, but can happen 
before, during, or after delivery. It can lead to seizures, kidney and liver damage, 
and death, and increases the risk of preterm births, low birth-weight, anemia, 
and stunting. Women who have PE/E have an increased risk of developing 
cardiovascular disease and other non-communicable diseases in later life. 
The World Health Organization (WHO) recommends magnesium sulphate 
(MgSO4) as the most effective, safe, and low-cost anticonvulsant treatment 
for severe pre-eclampsia and eclampsia. Twenty-eight countries include 
MgSO4 on their Essential Medicines List and have protocols on its use, but in 
practice, the drug is often unavailable at community facilities or is not used in 
compliance with guidelines.
PHC PE/E CORE MODEL DEVELOPMENT
Between 2008 and 2014, the Population Council implemented a two-
phase intervention, supported by the John D. and Catherine T. MacArthur 
Foundation, in Bangladesh, Mexico, and Nigeria. The first phase (2008-2011) 
involved training, mentoring, and supervising  providers at secondary facilities 
on detection and management of PE/E patients. This included training on the 
administration of a loading dose of MgSO4. The providers then trained and 
mentored additional providers at their respective health facilities on the use 
of MgSO4.
The second phase of the intervention (2012-2014) focused on primary health 
care (PHC) facilities, specifically on training PHC providers to administer a 
modified loading dose of MgSO4 (intra-muscular only) and refer women to 
secondary health facilities for monitoring. PHC providers received continued 
technical support from trainings and routine mentorship. 
The Council conducted an implementation research study to evaluate this 
task shifting process around the prevention, detection, and management of 
PE/E at the PHC level, hereby defined as the PHC PE/E Core Model. The study 
showed that not only were PHC providers effectively able to carry out this task, 
but maternal mortality in the intervention group decreased.
These components: Training PHC providers on detection and 
management of PE/E, administration of a loading dose of MgSO4, 
referral of women to secondary facilities for monitoring, and 
reinforcing proper detection and management of PE/E at secondary 
facilities are included in the PHC PE/E Core Model (Figure 1).
The Ending Eclampsia project seeks to expand 
access to proven,underutilized interventions and 
commodities for the prevention, early detection, 
and treatment of pre-eclampsia and eclampsia and 
strengthen global partnerships. 
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SCALE UP OF PHC PE/E CORE MODEL
The primary goal of the Ending Eclampsia project is 
to expand the use of MgSO4 and other underutilized 
commodities and strategies to prevent and treat pre-
eclampsia and eclampsia (PE/E). Collaborating with 
national policymakers, ministries of health, community 
leaders, and health providers to increase access to high-
impact, low-cost interventions. 
The Ending Eclampsia project has been implementing the 
PHC PE/E Core Model in select regions in Bangladesh, 
Nigeria, and Pakistan. Replicating the core activities 
was crucial to demonstrate that the PHC PE/E Core 
Model is acceptable and feasible in varied settings. 
Prior to initiating implementation of the PHC PE/E Core 
Model, any organization--whether a ministry of health, 
an international non-governmental organization, or 
a local organization--must consider the reality on the 
ground within the particular context. Monitoring data 
and preliminary analyses across these three countries 
indicate that task shifting of oral antihypertensive drugs 
to PHCs is feasible and effective. 
For the PHC PE/E Core Model to be the most 
effective (Figure 1), as with any complex health 
intervention, there is a certain health system 
context that must be in place. This includes:
• Supportive policy environment;
• Collaborative stakeholder engagement;
• Sustained funding for health;
• Operational infrastructure;
• Adequate and skilled human resources; and
• Functioning supply chain for essential drugs 
and commodities.
IDENTIFYING “PLUS” MODULES
Starting in 2016, Ending Eclampsia initiated six 
implementation research studies in three countries 
to identify and assess additional components that, in 
conjunction with the Core Model, can further improve 
prevention, detection, and management of PE/E. 
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FIGURE 1: PHC PE/Eplus Model
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Introducing antihypertensives at PHC
In Nigeria and Bangladesh, Ending Eclampsia introduced 
an antihypertensive drug (oral methyldopa) at PHC level 
to improve management of hypertension in pregnancy 
with the ultimate goal of preventing progression to PE/E. 
An antihypertensive drug module should be 
included, if possible, in efforts to improve 
prevention, detection, and management of PE/E 
(Figure 1). This module requires the availability 
of oral antihypertensive drugs that are safe for 
use in pregnancy (alpha methyldopa), training of 
PHC providers on the diagnosis of hypertension in 
pregnancy and administration of antihypertensive 
drugs, as well as how to provide adequate 
explanation of the condition, management 
protocols, and danger signs in pregnancy to 
women with high blood pressure.
Engaging community women’s groups (Nigeria)
Women’s group leaders were trained on health 
information that focused on antenatal care (ANC) and 
postnatal care (PNC) using a simplified pictorial job aid 
and log book to record activities. 
Trained women’s group leaders provide health education 
and information to their peers during their regular 
meetings. The expectation is that in doing so, more 
women will be empowered to use health facilities for 
themselves or to encourage their relatives for ANC/
PNC. In this way, ANC attendance, pre-eclampsia case 
detection and management, and quality of care for other 
services will improve. 
Community groups with women, men, or a mix 
of the genders, can be targeted as channels 
for sharing important health information with 
communities (Figure 1). Clear, pictorial job aids 
can be used to support the group leaders in 
delivering key health messages about danger 
signs in pregnancy, specifically PE/E to the 
members of their group. Increased awareness 
of PE/E can potentially lead to a woman seeking 
care sooner than she would otherwise if she were 
to experience complications in pregnancy. 
Task-shifting to community midwives (Pakistan)
Through implementation research conducted in Pakistan, 
researchers are assessing community midwives’ (CMWs)
ability to screen and detect PE/E cases, to provide a 
modified loading dose of MgSO4 to the appropriate 
clients, and to refer them for further management. 
In addition, this study aims to enhance the collaboration 
between CMWs and local health workers (LHWs) by 
encouraging LHWs to refer pregnant women for group 
ANC sessions provided by local CMWs, and to improve 
ANC and PNC counselling skills of CMWs so as to enable 
them to manage postpartum hypertension. 
Explore postnatal outcomes
About 25% of women with hypertensive disorders 
in pregnancy (HDPs), especially those with a severe 
condition, experience a deterioration of end organ 
functions during puerperium (period spanning 6 – 8 
weeks after delivery).In Bangladesh and Nigeria, Ending 
Eclampsia researched health outcomes of women and 
newborns after pregnancies complicated by HDPs and 
followed up with them at nine weeks, six months and 
one year after delivery to evaluate the nature of care 
they received, assess their health status, and identify any 
patterns in development of morbidities. 
Trained nurses and midwives at the maternity unit con-
duct follow ups, which include reviewing treatment re-
cords from delivery onward, performing routine medical 
checkups, and surveying participants.
The importance of postnatal care is not often 
emphasized enough in any context. Women 
who experienced hypertension in pregnancy are 
particularly susceptible to ongoing complications 
or morbidities. Therefore, we recommend that 
PNC becomes a focus for essential care of women 
with a history of hypertension in pregnancy 
(Figure 1.)
NEXT STEPS
Detailed results of the Ending Eclampsia project in each 
country will be available in 2019. Cross-country learnings 
will further refine the  PHC PE/Eplus Model as a framework 
for global policy, program, and research strategies to 
address the problem of hypertension in pregnancy 
in a context-sensitive way. A package of step-wise 
recommendations around task-shifting will be compiled 
and disseminated for integration within country-level 
maternal health strategies. At regional and global levels, 
Ending Eclampsia plans to share the PHC PE/Eplus model, 
related findings, and tools for adoption and scale up in 
varied settings.
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